VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study

VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study

Background: Perioperative chemotherapy plus surgery is one recommended standard treatment for patients with resectable gastric and esophageal cancer. Even with a multimodality treatment more than half of patients will relapse following surgical resection. Patients who have a poor response to neoadju...

Full description

Bibliographic Details
Main Authors: Elizabeth Smyth, Maren Knödler, Anne Giraut, Murielle Mauer, Magnus Nilsson, Nicole Van Grieken, Anna Dorothea Wagner, Markus Moehler, Florian Lordick
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-01-01
Series:Frontiers in Oncology
Subjects:
gastric cancer
gastroesophageal cancer
immunotherapy
chemotherapy
adjuvant
nivolumab
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.01320/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.01320/full

Similar Items